🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔬✨ Estrategias flexibles en cáncer de mama metastásico 🩺 Un estudio liderado por la Dra. Paola Zagami, MD destaca cómo el cambio entre inhibidores CDK4/6 por toxicidades inaceptables está transformando la práctica clínica en HR+/HER2-. 💡 La experiencia de oncólogos italianos

We mourn the untimely passing of Giovanni Scambia, a visionary leader in European gynecologic oncology. His pioneering contributions, dedication to patient care, and commitment to advancing research have left an indelible mark ESMO - Eur. Oncology ASCO

It is a great honor to present at #ASCO25. Thanks a lot to Matteo Lambertini, MD PhD and team, Yara Abdou, MD, MSCR Lisa Carey, MD, ScM, FASCO!! See you in Chicago! G Curigliano MD PhD IEO UNC Lineberger Università degli Studi di Milano

Lo dico sempre che abbiamo molti talenti tra i nostri giovani medici e ricercatori. Complimenti a tutti. shorturl.at/8ciWx

It was a great honor to meet Kevin Kalinsky, MD, MS, FASCO,amazing oncologist and beautiful person! Thanks a lot for your and dr Keir support, endorsing my ASCO conquer cancer merit awar🏅. Great and interesting presentation of NATALEE trial by age and menopausal! Conquer Cancer, the ASCO Foundation #ASCO25

Today at #ASCO25, Paola Zagami, MD, will present at the oral abstract session on the impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international

Paola Zagami, MD presents info re: BRCA carriers; 1865 pts looking again at tam, tam + OFS, and AI + OFS 💫 very simply, OFS improved survival! Fantastic presentation, I've been told Paola Zagami, MD is a fellow currently w/ G Curigliano MD PhD ..watch out for this up and comer! #ASCO25 #bcsm

Excellent presentation by Paola Zagami, MD showing OFS + ET improved DFS and OS in a global cohort of young BRCA mutation carriers! Proud of you 👏🏼 👏🏼🤩 #ASCO25 #bcsm OncoAlert Matteo Lambertini, MD PhD

#ASCO25 Oral Abstract Session eBC Presented by Paola Zagami, MD insights on adjuvant ET from the BRCA BCY collab led by Matteo Lambertini, MD PhD In young BRCA carriers, OFS+ET significantly improved outcomes vs tam: DFS aHR 0.79 OS aHR 0.66 OFS is essential also in BRCA carriers! OncoAlert

More data from the #BRCABCYcollaboration at #ASCO25 presented by Paola Zagami, MD showing the benefit of ovarian function suppression as adjuvant endocrine therapy in young #BRCA carriers with #BreastCancer OncoAlert Eva Blondeaux ASCO

BRCA BCY global study with 1 ,865 BRCA mutations carriers with HR+ BC where SUMA 🇦🇷 participated actively provides evidence that OFS combined with ET improved DFS and OS Paola Zagami, MD Matteo Lambertini, MD PhD #ASCO25

In a large (n=1865) retrospective cohort of pts with BRCA mut and HR+ eBC, the addition of OFS to ET was found to significantly improve DFS & OS. Terrific presentation by Paola Zagami, MD! Congrats to mentors G Curigliano MD PhD / Lisa Carey, MD, ScM, FASCO & Matteo Lambertini, MD PhD leader of this impressive database!

Amazing presentation by my senior Italian colleague Paola Zagami, MD on the impact of OFS with adjuvant ET on survival in young BRCA-mutated breast cancer pts. So proud to see female Italian oncologists thrive—huge thanks to all her mentors and her mentor abroad Lisa Carey, MD, ScM, FASCO 🙏🏻

Commitment,skills powered by supporting mentorship results in raising stars 🌟 pointing 👉 to the direction best #cancer care goes toward! RN at #ASCO24 Dr Paola Zagami, MD 🩺 showed how smart ideas within collaborative group & trust in young researchers can deliver better #bcsm care!

📌 The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline 🧬BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study. ✨Paola Zagami, MD 👏🏻 OncoAlert #OncoAlertAF #ASCO25

At #ASCO25, Paola Zagami, MD reported findings from int’l study: Treating young breast cancer pts who have BRCA mutation with ovarian function suppression+adjuvant endocrine therapy improved breast cancer-free interval & disease-free and overall survival. #BCSM

Paola Zagami, MD presented data supporting that in young women w/ HR+ breast cancer & BRCA mutations, adding ovarian suppression (OFS) to endocrine therapy improved disease-free & overall survival compared to tamoxifen alone. Supports OFS as key in adjuvant care for this group #ASCO25

The best ASCO of my life. Honorated to be selected together with amazing G Curigliano MD PhD 💥

Paola Zagami, MD Conquer Cancer, the ASCO Foundation Honor was all ours! You did a fantastic job! Huge congrats!!!

IEO G Curigliano MD PhD Paola Zagami, MD So wonderful Paola! Huge congratulations!! 👏🏽